# C_2015249EN.01001401.xml

| 30.7.2015 | EN | Official Journal of the European Union | C 249/14 |
| --- | --- | --- | --- |

30.7.2015

EN

Official Journal of the European Union

C 249/14

---

Prior notification of a concentration

(Case M.7685 — Perrigo/GSK Divestment Businesses)

(Text with EEA relevance)

(2015/C 249/13)

| 1. | On 22 July 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Perrigo Company Plc (‘Perrigo’, Ireland) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the assets constituting certain consumer healthcare businesses (the ‘Divestment Businesses’) of GlaxoSmithKline Consumer Healthcare Holdings Limited (‘GSK’, United Kingdom), by way of purchase of assets. |
| --- | --- |

1.

On 22 July 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Perrigo Company Plc (‘Perrigo’, Ireland) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the assets constituting certain consumer healthcare businesses (the ‘Divestment Businesses’) of GlaxoSmithKline Consumer Healthcare Holdings Limited (‘GSK’, United Kingdom), by way of purchase of assets.

1

| 2. | The business activities of the undertakings concerned are:
  —   for Perrigo: the development, manufacture, and marketing of consumer healthcare and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients (APIs), globally;
  —   for GSK Divestment Businesses: (i) nicotine reduction therapies (NiQuitin); (ii) cold & flu treatments (Coldrex, Nasin and Nezeril); (iii) pain management treatments (Panodil); and (iv) topical cold sores management treatments (including Fenivir, Pencivir, Vectavir, and Vectatone). |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Perrigo: the development, manufacture, and marketing of consumer healthcare and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients (APIs), globally;

for Perrigo

—   for GSK Divestment Businesses: (i) nicotine reduction therapies (NiQuitin); (ii) cold & flu treatments (Coldrex, Nasin and Nezeril); (iii) pain management treatments (Panodil); and (iv) topical cold sores management treatments (including Fenivir, Pencivir, Vectavir, and Vectatone).

for GSK Divestment Businesses

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7685 — Perrigo/GSK Divestment Businesses, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7685 — Perrigo/GSK Divestment Businesses, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---